A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide

StatusRecruiting
PhasePhase 1
SponsorKailera
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened
    • Study sites: 1 to 2
    • Eligibility criteria shortened, about 10 words
  2. Study sites: 0 to 1
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Kailera
7 trials monitored
See all monitored trials
Obesity
3,888 trials monitored
See 157 trials at risk
Chronic Kidney Disease
1,423 trials monitored
See 70 trials at risk
The primary objective of the study is to estimate the PK parameters of ribupatide in participants with severe renal impairment or end-stage kidney disease (ESKD) after a single dose of ribupatide subcutaneous (SC) injection compared with participants with normal renal function.
Trial Details
NCT Number NCT07793929
Lead Sponsor Kailera
Conditions
(from sponsor)		 End Stage Renal Disease, Renal Impairment, Obesity, Overweight
Related terms Kidney Failure, Chronic, Obesity, Overweight, Renal Insufficiency
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov